SCHEDULE 13G/A 0001104659-25-010521 0001704131 XXXXXXXX LIVE 1 Common Stock, par value $0.001 09/30/2025 0001842295 Maze Therapeutics, Inc. 578784100 171 Oyster Point Blvd., Suite 300 South San Francisco CA 94080 Rule 13d-1(c) Foresite Capital Fund IV, L.P. b DE 522657.00 0.00 522657.00 0.00 522657.00 N 1.2 PN Note to Row 5: 522,657 shares, except that Foresite Capital Management IV, LLC ("FCM IV"), the general partner of Foresite Capital Fund IV, L.P. ("FCF IV"), may be deemed to have sole power to vote these shares, and James Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 522,657 shares, except that FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 43,850,884 Common Stock outstanding of Maze Therapeutics, Inc. (the "Issuer") as of August 6, 2025, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025. Foresite Capital Management IV, LLC b DE 522657.00 0.00 522657.00 0.00 522657.00 N 1.2 OO Note to Row 5: 522,657 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 522,657 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 43,850,884 Common Stock outstanding of the Issuer as of August 6, 2025, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025. Foresite Capital Fund V, L.P. b DE 86291.00 0.00 86291.00 0.00 86291.00 N 0.2 PN Note to Row 5: 86,291 shares, except that Foresite Capital Management V, LLC ("FCM V"), the general partner of Foresite Capital Fund V, L.P. ("FCF V"), may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 86,291 shares, except that FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 43,850,884 Common Stock outstanding of the Issuer as of August 6, 2025, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025. Foresite Capital Management V, LLC b DE 86291.00 0.00 86291.00 0.00 86291.00 N 0.2 OO Note to Row 5: 86,291 shares, all of which are directly owned by FCF V. FCM V, the general partner of FCF V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 86,291 shares, all of which are directly owned by FCF V. FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 43,850,884 Common Stock outstanding of the Issuer as of August 6, 2025, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025. James Tananbaum b X1 608948.00 0.00 608948.00 0.00 608948.00 N 1.4 IN Note to Row 5: 608,948 shares, of which 522,657 shares are directly owned by FCF IV and 86,291 shares are directly owned by FCF V. Tananbaum is the managing member of each of FCM IV, which is the general partner of FCF IV, FCM V, which is the general partner of FCF V. Tananbaum may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 608,948 shares, of which 522,657 shares are directly owned by FCF IV and 86,291 shares are directly owned by FCF V. Tananbaum is the managing member of each of FCM IV, which is the general partner of FCF IV, FCM V, which is the general partner of FCF V. Tananbaum may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 43,850,884 Common Stock outstanding of the Issuer as of August 6, 2025, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025. Maze Therapeutics, Inc. 171 Oyster Point Blvd., Suite 300 South San Francisco, CA, 94080 This Schedule is filed by Foresite Capital Fund IV, L.P., a Delaware limited partnership, Foresite Capital Management IV, LLC, a Delaware limited liability company, Foresite Capital Fund V, L.P., a Delaware limited partnership, Foresite Capital Management V, LLC, a Delaware limited liability company and James Tananbaum. The foregoing entities and individuals are collectively referred to as the "Reporting Persons." c/o Foresite Capital Management 900 Larkspur Landing Circle, Suite 150 Larkspur, CA 94939 See Row 4 of cover page for each Reporting Person. Y See Row 9 of cover page for each Reporting Person. See Row 11 of cover page for each Reporting Person. See Row 5 of cover page for each Reporting Person. See Row 6 of cover page for each Reporting Person. See Row 7 of cover page for each Reporting Person. See Row 8 of cover page for each Reporting Person. N Y N Under certain circumstances set forth in the limited partnership agreements of FCF IV and FCF V and the limited liability company agreements of FCM IV and FCM V, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of the Issuer shall be filed on behalf of each of the undersigned. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate agencies. Foresite Capital Fund IV, L.P. /s/ James Tananbaum 11/14/2025 Foresite Capital Management IV, LLC /s/ James Tananbaum 11/14/2025 Foresite Capital Fund V, L.P. /s/ James Tananbaum 11/14/2025 Foresite Capital Management V, LLC /s/ James Tananbaum 11/14/2025 James Tananbaum /s/ James Tananbaum 11/14/2025